Información del artículo
Estudios recientes sugieren que la utilización de determinados psicofármacos, en combinación con terapia comportamental, puede ser de utilidad en la rehabilitación de las afasias, para acelerar la recuperación del lenguaje. En este artículo presentamos una revisión actualizada del tratamiento farmacológico de las afasias, centrada en las investigaciones con los compuestos sobre los que hay mayor evidencia clínica: bromocriptina, anfetaminas, donepezilo y piracetam.
Palabras clave:
Afasia
Farmacoterapia
Bromocriptina
Anfetaminas
Donepezilo
Piracetam
Recent studies suggest that the use of certain psychotropic drugs in combination with behavior therapy can be useful in the treatment of aphasia, accelerating language recuperation. We provide an update of pharmacological treatments for aphasia, focusing on the compounds for which there is greatest clinical evidence: bromocriptine, amphetamines, donepezil and piracetam.
Keywords:
Aphasia
Pharmacotherapy
Bromocriptine
Amphetamines
Donepezil
Piracetam
Artículo
Opciones para acceder a los textos completos de la publicación Psiquiatría Biológica
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
Walker-Boston D..
Use of pharmacotherapy in the treatment of aphasia..
Brain Lang, 71 (2000), pp. 252-4
[2]
Wallesch CW, Muller U, Herrmann M..
Aphasia. Role of pharmacotherapy in treatment..
CNS Drugs, 7 (1997), pp. 203-13
[3]
Gold M, VanDam D, Silliman ER..
An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval..
Brain Lang, 74 (2000), pp. 141-56
[4]
Stuctural and functional brain imaging. En: D Vogel, M Cannito, editors. Treating disordered speech motor control. Austin: PRO-ED; 1991.
[5]
Muller Y, Von Cramon Y..
The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage..
Prog NeuroPsychopharmacol Biol Psychiatr, 18 (1994), pp. 1103-20
[6]
Albert M, Bachman D, Morgan A, Helm-Estabrooks N..
Pharmacotherapy for aphasia..
Neurology, 38 (1988), pp. 877-9
[7]
Bachman D, Morgan A..
The role of pharmacotherapy in the treatment of aphasia: preliminary results..
Aphasiology, 2 (1988), pp. 225-8
[8]
Gupta SR, Mlcoch AG..
Bromocriptine treatment of nonfluent aphasia..
Arch Phys Med Rehab, 73 (1992), pp. 373-6
[9]
Gupta SR, Mlcoch AG, Scolaro C, Moritz T..
Bromocriptine treatment of nonfluent aphasia..
Neurology, 42 (1995), pp. 2170-3
[10]
Sabe L, Leiguarda R, Starkstein SE..
An open-label trial of bromocriptine in nonfluent aphasia..
Neurology, 42 (1992), pp. 1637-8
[11]
Leiguarda R, Merello M, Sabe L, Starkstein S..
Bromocriptine-induced dystonia in patients with aphasia and hemiparesis..
Neurology, 43 (1993), pp. 2319-22
[12]
Sabe L, Salvarezza F, Cuerva AG, Leiguarda R, Starkstein S..
A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia..
Neurology, 45 (1995), pp. 2272-4
[13]
Ozeren A, Sarica Y, Mavi H, Demirkiran M..
Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia..
Acta Neurol Belg, 95 (1995), pp. 235-8
[14]
Bragoni M, Altieri M, Di Piero V, Padovani A, Mostardini C, Lenzi GL..
Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke..
Neurol Sci, 21 (2000), pp. 19-22
[15]
Naeser MA, Palumbo CL, Helm-Estabrooks N, Stiassny-Eder D, Albert M..
Severe no fluency aplasia. Role of the medial subcallosal fasciculus and other white matter pathways in recovery of spontaneous speech..
Brain, 112 (1989), pp. 1-38
[17]
Feeney DM..
Pharmacological modulation of recovery after brain injury..
Crit Rev Neurobiol, 3 (1987), pp. 135-97
[18]
Deitrich WD, Alonso O, Busto R, Ginsberg MD..
The effect of amphetamine on functional brain activation in normal and post-infarcted rat..
Stroke, 21 (1990), pp. 147-50
[19]
Gold PE, Delaney RL, Merrin J..
Modulation of long-term potentiation by peripherally administered amphetamine and epinephrine..
Brain Res, 305 (1984), pp. 103-7
[20]
Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, et al..
Modulation of use-dependent plasticity by D-amphetamine..
Ann Neurol, 51 (2002), pp. 59-68
[21]
Knecht S, Imai T, Kamping S, Breitenstein C, Henningsen H, Lutkenhoner B, et al..
D-amphetamine does not improve outcome of somatosensory training..
Neurology, 57 (2001), pp. 2248-52
[22]
Walker-Batson D, Unwin H, Curtis S, Allen E, Wood M, Smith P, et al..
Use of amphetamine in the treatment of aphasia..
Rest Neurol Neurosci, 4 (1992), pp. 47-50
[23]
McNeil MR, Doyle PJ, Spencer KA, Goda AJ, Flores D, Small SL..
A double-blind, placebo-controlled study of pharmacological and behavioural treatment of lexical-semantic deficits in aphasia..
Aphasiology, 11 (1997), pp. 385-400
[24]
Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al..
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia..
Stroke, 32 (2001), pp. 2093-7
[25]
Martinsson L, Wahlgren NG..
Safety of dexamphetamine in acute ischemic stroke. A randomized, double-blind, controlled dose-escalation trial..
Stroke, 34 (2003), pp. 475-81
[26]
Berthier ML, Hinojosa J, Martin MD, Fernández I..
Open-label study of donepezil in chronic poststroke aphasia..
Neurology, 60 (2003), pp. 1218-9
[27]
Enderby P, Broeck J, Hospers W, Schildermans F, Deberdt W..
Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study..
Clin Neuro pharmacol, 17 (1994), pp. 320-1
[28]
Huber W, Willmes K, Poeck K, Van Vleymen B, Deberdt W..
Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study..
Arch Phys Med Rehab, 78 (1997), pp. 245-50
[29]
Piracetam in the treatment of acute stroke. CNS Drugs. 1998;9 Suppl 1:41-9.
[30]
Kessler J, Thiel A, Karbe H, Heiss WD..
Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients..
Stroke, 31 (2000), pp. 2112-6
[31]
Szelies B, Mielke R, Kessler J, Heiss WD..
Restitution of alpha-topography by piracetam in post-stroke aphasia..
Int J Clin Pharm Ther, 39 (2001), pp. 152-7
[32]
Small SL..
The future of aphasia treatment..
Brain Lang, 71 (2000), pp. 227-32
